The Cooper Companies, Inc. $COO Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lowered its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 51.3% in the third quarter, HoldingsChannel reports. The firm owned 10,746 shares of the medical device company’s stock after selling 11,310 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Cooper Companies were worth $737,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Cooper Companies by 1.8% during the second quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock valued at $1,725,963,000 after acquiring an additional 421,423 shares during the period. State Street Corp boosted its stake in Cooper Companies by 1.2% during the 2nd quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock valued at $616,227,000 after purchasing an additional 104,910 shares during the period. Geode Capital Management LLC grew its position in Cooper Companies by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock worth $368,893,000 after purchasing an additional 127,907 shares during the last quarter. Ameriprise Financial Inc. grew its position in Cooper Companies by 98.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock worth $241,120,000 after purchasing an additional 1,683,561 shares during the last quarter. Finally, Sustainable Growth Advisers LP bought a new stake in shares of Cooper Companies during the second quarter valued at approximately $240,881,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Price Performance

COO opened at $82.99 on Monday. The stock has a fifty day moving average of $81.83 and a 200-day moving average of $74.84. The firm has a market capitalization of $16.26 billion, a P/E ratio of 44.14, a PEG ratio of 2.37 and a beta of 1.03. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $93.00.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Lawrence Erik Kurzius purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was bought at an average cost of $82.50 per share, for a total transaction of $165,000.00. Following the completion of the acquisition, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. The trade was a 34.62% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Maria Rivas bought 1,000 shares of the stock in a transaction on Thursday, December 18th. The stock was acquired at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the acquisition, the director directly owned 11,141 shares in the company, valued at approximately $915,010.33. The trade was a 9.86% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 16,014 shares of company stock valued at $1,304,416 in the last three months. Company insiders own 1.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on COO. Stifel Nicolaus set a $95.00 price objective on Cooper Companies and gave the stock a “buy” rating in a report on Friday, December 5th. The Goldman Sachs Group reissued a “sell” rating and issued a $73.00 price target on shares of Cooper Companies in a research note on Friday, January 9th. William Blair upgraded shares of Cooper Companies to a “strong-buy” rating in a research note on Friday, January 30th. Barclays set a $98.00 target price on shares of Cooper Companies and gave the company an “overweight” rating in a research report on Monday, January 26th. Finally, KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cooper Companies currently has an average rating of “Moderate Buy” and an average price target of $90.77.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.